Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST-1002
- Development stage
- Discontinued
- Lead developer
- BioStratum
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BST-1002 is an experimental anti-angiogenic and anti-neoplastic agent developed by BioStratum. It is a recombinant version of Tumstatin, a 28-kDa fragment derived from the non-collagenous (NC1) domain of the alpha 3 chain of type IV collagen. BST-1002 exerts its therapeutic effects by binding to alpha V beta 3 (αvβ3) integrins on the surface of vascular endothelial cells. This binding triggers a signaling cascade that inhibits cap-dependent protein translation and induces apoptosis in these cells, thereby suppressing tumor angiogenesis and growth. The development of BST-1002 was part of BioStratum's focus on basement membrane-derived proteins for the treatment of cancer and other diseases, though development appears to have ceased following the company's financial restructuring.
- Other names
- Tumstatin
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on BST-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST-1002.